Cardiology

The phase 3 trial suggest obicetrapib offered significant reductions in LDL-C when added to maximally tolerated lipid-lowering therapy in HeFH.

A study found wearable devices alerting irregular heart rhythms amplified anxiety in 1 in 5 participants with atrial fibrillation, which led people to be more likely to seek care.

Personalized text messages can boost physical activity in cardiac rehab patients, especially in early stages, but effectiveness varies by time and device, study finds.

UAB research shows AHA’s Life’s Essential 8 and Simple 7 scores aid public health but are less effective than pooled cohort equations for predicting individual cardiovascular risk.

Despite recommendations, an analysis of more than 3.2 million youths suggests fewer than 15% of children/adolescents receive lipid screening.

Bludorn joins Lungcast to review the increasing effects and signs of heat-related illness amid record-high temperatures.

Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.

A new study showed the efficiency and speed of a new AI model for a heart scan.

In this episode, John Buse, MD, PhD, discusses the background, expected prevalence, reaction to results, and the importance of the second part of the CATALYST trial.

Neuen explains the cardiovascular and kidney benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists in diabetes and the future of combination therapy.

Promoting adherence to a Mediterranean diet in children improves cardiometabolic health biomarkers, according to a new study.

A study showed participants with symptoms of anxiety and depression had significantly fewer controlled cardiovascular disease risk factors.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

Approximately 1454 counties with 2 million residents have no cardiologist in the US, primarily affecting rural and socioeconomically disadvantaged areas.

Our Cardiology Month in Review for June 2024 spotlights the pharmacotherapies making waves within the pipeline, the latest news in dyslipidemia, and updates in heart failure.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

A review of nearly 500 studies spanning more than 30 years details associations between weather events and cardiovascular risk.

The panelists stress the significance of a comprehensive approach to patient care, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

The panel explores issues surrounding medication adherence and the potential for improved patient engagement. They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Anjali Tiku Owens, MD, examines mavacamten, the pioneering cardio myosin inhibitor (CMI) approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), which is exclusively accessible through the restricted Risk Evaluation and Mitigation Strategy (REMS) program; the KOL delves into the objectives of this program and how it strives to enhance medication safety and optimize patient outcomes.